ASCO 2023 | Phase I study of CD5 CAR-T therapy manufactured with TKIs in R/R T-ALL
LaQuisa Hill
• 2 Jun 2023
LaQuisa Hill, MD, Baylor College of Medicine, Houston, TX, shares the results of a Phase I study evaluating CD5-directed CAR-T therapy for patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL; NCT03081910). Dr Hill explains that whilst administering the CAR-T product alone led to suboptimal response rates, manufacturing CD5-CAR-Ts with tyrosine kinase inhibitors (TKIs) led to improved potency and anti-tumor activity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
